Analytical dilemmas in assessing efficacy of radical cure of vivax malaria
The radical cure for Plasmodium vivax malaria involves administration of blood schizontocidal drug(s) against the acute attack and a hypnozoitocidal drug for the prevention of relapse due to latent hepatic stages of the parasite.1 There are many options for the former but just two for the latter: primaquine given daily for 7 or 14 days; or a single dose of tafenoquine. Currently the malaria control programme in India recommends 14 days of daily primaquine for radical cure of P. vivax.
Authors
- J Kevin Baird (ORCID: https://orcid.org/0009-0000-7446-958X)
Institutions
- University of Indonesia (ID)
- University of Oxford (GB)
Publication Details
- Journal
- The Lancet Regional Health - Southeast Asia
- Published
- 2026-09-10
- DOI
- https://doi.org/10.1016/j.lansea.2026.100867
- Primary Topic
- Malaria Research and Control
- Type
- article
- Field-Weighted Citation Impact
- 0.00